CXCR4-PET/CT for Diagnosing Giant Cell Arteritis

Diagnoses Disease Clinical Trial

Official title: Detection of Disease Activity in Giant Cell Arteritis Using CXCR4-PET/CT

Status Completed

Clinical Trial Summary

Giant cell arteritis (GCA) is the most common vasculitis in the elderly. Accurate diagnosis is of utmost importance in order to then initiate the necessary immunosuppressive therapy. For large-vessel GCA (LV-GCA) involving the aorta and its branches, FDG-PET/CT is the standard in imaging for diagnosis and is recommended by the guidelines. However, this only indirectly visualizes inflammation through vessel wall uptake of glucose. A new PET tracer, 68Ga-pentixafor, is used to visualize the chemokine receptor CXCR4. This receptor is expressed by cells of the immune system. In the context of inflammatory processes, upregulation of CXCL12, the ligand of CXCR4, occurs in affected tissues. The chemotactic effect of this ligand leads to the immigration of CXCR4-positive inflammatory cells into the inflamed area, which can be visualized by PET using the CXCR4-specific tracer 68Ga-Pentixafor. The value of CXCR4-PET should therefore be tested in the context of LV-GCA. This study tests the benefit of CXCR4 in therapy-naïve patients with suspected LV-GCA. For this purpose, patients will receive a FDG-PET and a CXCR4-PET for direct comparison. This is an imaging-only study. Therapy will not be affected by the study. The study is single-arm and not blinded.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Arteritis
• Diagnoses Disease
• Giant Cell Arteritis
• Polymyalgia Rheumatica
• Vasculitis

• NCT number: NCT05604482
• Study type: Interventional
• Source: Wuerzburg University Hospital
• Status: Completed
• Phase: N/A
• Start date: October 1, 2021
• Completion date: September 30, 2023